Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the giant-cell arteritis market?

In recent times, the market size of giant-cell arteritis has experienced substantial growth. The forecast suggests an increase from $1.07 billion in 2024 to $1.12 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.3%. Various factors contribute to this historic growth, including epidemiological research, genetic discoveries, a growing preference for biologics, advances in diagnostic procedures, and the evolution of targeted treatments and biologics.

What will be the giant-cell arteritis market size in the future?

Expectations for the market size of giant-cell arteritis indicate consistent expansion over the next years. By 2029, the market is expected to reach $1.36 billion, with a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period can be linked to a variety of factors, including improved diagnosis rates, an older population, increased health care spending, patient advocacy, and market expansion into novel geographic areas. Expectations for major trends within this period encompass advancements in biomarker identification and validation, the development of therapy targeting specific molecular pathways, the adoption of cutting-edge imaging technologies, advancements in drug delivery, and the implementation of artificial intelligence for predictive analytics.

Get your giant-cell arteritis market report here!

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

What main drivers are fueling expansion in the giant-cell arteritis market?

The giant-cell arteritis market is set to grow due to the increasing focus on personalized medicine. This approach to treatment, which is based on individual characteristics such as genetics, lifestyle, and environment, is on the rise, fueled by advancements in genomics, biotechnology, and data analytics. Such advancements facilitate the development of targeted therapies that can enhance the effectiveness of treatment and minimize adverse effects. As far as giant-cell arteritis (GCA) is concerned, personalized medicine can deliver targeted therapies tailored to various patient factors like genetic predispositions, immune profiles, and disease manifestations. The Personalized Medicine Coalition (PMC), a non-profit organization based in the U.S., revealed in February 2024 that over a third of new drug approvals by the U.S. Food and Drug Administration (FDA), for the fourth year running, were personalized medicines in 2023. That year, the FDA gave the green light to 16 new personalized treatments for rare diseases, a significant rise from just six in 2022. The approvals in 2023 also included seven cancer drugs and three treatments for various other medical conditions. Thus, the burgeoning emphasis on personalized medicine is fuelling the growth of the giant-cell arteritis market.

What key areas define the segmentation of the global giant-cell arteritis market?

The giant-cell arteritis market covered in this report is segmented –

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

Who are the dominant players expanding their reach in the giant-cell arteritis market?

Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

What key trends are currently impacting the giant-cell arteritis market’s development?

Leading organizations within the giant-cell arteritis market are innovating new offerings including biosimilars, in an effort to broaden treatment methods and cater to the unaddressed needs within patient care. Biosimilars refer to biologic medicines that closely resemble an approved biological product, with no major discrepancies concerning safety, purity, and potency. The healthcare company based in Germany, Fresenius SE & Co. KGaA, in April 2024, introduced a new product called Tocilizumab-aazg intended for patients with chronic autoimmune diseases within the US market. This biosimilar has gained approval for treating diseases like rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), as well as giant cell arteritis. Approval was granted based on evidence derived from a randomized, double-blind, single-dose, parallel phase 1 trial. Comparison of its pharmacokinetics, safety, and immunogenicity was done against both US and EU reference tocilizumab across three different patient groups.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162

Which regions are emerging as leaders in the giant-cell arteritis market?

North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cell Based Assays Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Cell Culture Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Stem Cell Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: